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Abstract
Introduction Morbid obesity is an important risk factor for developing a venous thromboembolic events (VTE) after surgery.
Fast-track protocols in metabolic surgery can lower the risk of VTE in the postoperative period by reducing the immobilization
period. Administration of thromboprophylaxis can be a burden for patients. This study aims to compare extended to restricted
thromboprophylaxis with low molecular weight heparin (LMWH) for patients undergoing metabolic surgery.
Methods In this single center retrospective cohort study, data was collected from patients undergoing a primary Roux-en-Y
gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2014 and 2018. Patients operated in 2014–2017 received
thromboprophylaxis for two weeks. In 2018, patients only received thromboprophylaxis during hospital admission. Patients
already using anticoagulants were analyzed as a separate subgroup. The primary outcome measure was the rate of clinically
significant VTEs within three months. Secondary outcome measures were postoperative hemorrhage and reoperations for
hemorrhage.
Results 3666 Patients underwent a primary RYGB or SG following the fast-track protocol. In total, two patients in the 2014–
2017 cohort were diagnosed with VTE versus zero patients in the 2018 cohort. In the historic group, 34/2599 (1.3%) hemor-
rhages occurred and in the recent cohort 8/720 (1.1%). Postoperative hemorrhage rates did not differ between the two cohorts
(multivariable analysis, p = 0.475). In the subgroup of patients using anticoagulants, 21/347(6.1%) patients developed a postop-
erative hemorrhage. Anticoagulant use was a significant predictor of postoperative hemorrhage (p < 0.001).
Conclusion Despite the restricted use of thromboprophylaxis administration since 2018, the rate of VTEs did not increase. This
may be explained by quick mobilization and hospital discharge, as encouraged by the fast-track protocol. There was no
significant difference in postoperative hemorrhage rates by thromboprophylaxis protocol. Short term use of thromboprophylaxis
in metabolic surgery is safe in patients at low risk of VTE.
Keywords Roux-en-Y gastric bypass . Sleeve gastrectomy . Hemorrhage . Pulmonary embolism . Deep venous thrombosis .
ERABS . Enhanced recovery
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Introduction
Severe obesity (body mass index (BMI) ≥ 40 kg/m2) is asso-
ciated with increased mortality rates, with most deaths attrib-
uted to heart disease, cancer and diabetes [1]. These increased
risks can largely be reversed by significant weight loss, which
is most permanently achieved by metabolic surgical proce-
dures [2]. Whilst these procedures are safe, morbidly obese
patients are at increased risk of developing short-term postop-
erative complications [3, 4]. Reduction of BMI-related health
risks are thought to outweigh the risks of metabolic surgery
such as venous thromboembolic events (VTE) with high mor-
tality rates [5].
Rates of deep venous thrombosis (DVT) and pulmonary
embolism (PE) after metabolic surgery are moderate: 0.3–
2.2% within one month after surgery for DVT and 1% for
PE [4]. Nevertheless, PE plays an important role in the mor-
tality of this patient category and guidelines advice to admin-
ister prophylactic low molecular weight heparin (LMWH)
perioperatively and after discharge to all patients undergoing
metabolic surgery [6, 7]. There is no consensus on type, dos-
age or duration of prophylaxis, but a recent publication from
the American Society for Metabolic and Bariatric Surgery
(ASMBS) Clinical Issues Committee suggested that extended
pharmacological thromboprophylaxis can be restricted to only
those patients who are deemed high risk of developing venous
thromboembolic events (VTEs) [6]. Guidelines for periopera-
tive care in metabolic surgery with respect to the Enhanced
Recovery After Bariatric Surgery (ERABS) protocols recom-
mend early mobilization and mechanical prophylaxis, such as
intermittent pneumatic compression or graduated compres-
sion stockings. However, there are also guidelines that addi-
tionally encourage extended use of thromboprophylaxis for
three to four weeks [7]. The effect of exclusive preoperative
and/or extended pharmacological thromboprophylaxis on the
incidence of postoperative bleeding is currently unknown.
Over the years, multiple studies have been published on the
advantages of following an ERABS protocol. One of the most
important items in these fast-track protocols is to stimulate
early mobilization after surgery, thereby allowing for early
hospital discharge and reducing the number of VTEs. At the
same time, the fast-track program aims to prevent overtreat-
ment with potentially unnecessary pharmacological
thromboprophylaxis. Studies suggest that the rate of VTE af-
ter laparoscopic metabolic surgery nowadays is relatively low
[8, 9], while the incidence of major bleeding seems to increase
[10, 11]. Thus, not only preventive measures for VTE should
be undertaken, but also for postoperative hemorrhage.
This study aims to investigate if the VTE risk of restricted
LMWH prophylaxis is sufficiently low in patients undergoing
metabolic surgery with no or little risk factors besides their
obesity. In addition, we assessed whether the risk of postop-
erative hemorrhage decreased when the duration of
thromboprophylaxis was shortened.
Methods
Design and Data Collection
We performed a retrospective cohort study using two cohorts
(details mentioned below). Data was collected prospectively
from all patients undergoing a primary Roux-en-Y gastric
bypass (RYGB) or sleeve gastrectomy (SG) between
January 2014 and December 2018 in a single center teaching
hospital. The mean (± SD) duration of surgery was 53 ±
19 min for RYGB and 36 ± 13 min for SG. The median
(IQR) length of hospital stay for the complete cohort was
1.17 (0.18) days. The primary outcome measure was the clin-
ically significant VTE within three months postoperatively.
Secondary outcome measures were postoperative hemorrhage
within one month and reoperation for postoperative hemor-
rhage within one month.
Cohorts
All patients were treated in accordance with the ERABS pro-
tocol in use in that period [12]. Two cohorts were formed
according to the two regimens of thromboprophylaxis; I)
2014–2017: Extended thromboprophylaxis: Dalteparin
5000 IE from 12 h pre-operatively until two weeks postoper-
a t i v e l y f o r a l l p a t i e n t s ; I I ) 2 018 : Re s t r i c t e d
thromboprophylaxis: Dalteparin 5000 IE only during hospital
admission, starting postoperatively. High risk patients were
identified according to the Caprini score (Table 1) [13] and
received pharmacological thromboprophylaxis according to
the 2014–2017 protocol: Dalteparin 5000 IE starting the day
before surgery and continuing until two weeks postoperative-
ly. Patients who had had previous VTEs were advised to wear
their own stockings. Patients using vitamin K antagonists
(VKAs) or direct oral anticoagulants (DOACs) would bridge
the perioperative period using a prophylactic dosage of
Dalteparin instead of therapeutic, because of the non-
negligible risk of postoperative hemorrhage.
The protocol alteration to restricted thromboprophylaxis in
2018 was implemented because the risk of hemorrhage was
thought to exceed the risk of VTE and based on gained expe-
rience with pharmacological thromboprophylaxis, and sup-
ported by the work of Blanchet et al., showing that extended
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pharmacological prophylaxis can increase the incidence of
postoperative bleeding [11].
Types of Surgery
The surgical techniques did not change over the years for any
of the procedures [14–16]. For SG, clips are applied on the
staple line in case of visible bleeding in normotensive patients.
In some cases of peroperative bleeding, a drain is placed,
which is removed the next day in case of no or little produc-
tion. The RYGB is checked at the entero-enterostomy and
gastro-enterostomy for bleeding spots. During the operation
and certainly towards the end, the aim is to keep the patient
normotensive and to control the possible bleeding spots
properly.
Postoperative Complications
VTE was defined as clinically apparent VTE, as no routine
venous duplex ultrasound of the calf veins was performed. On
the first postoperative day, patients were asked about com-
plaints of calf pain as part of the ERABS protocol postopera-
tive checklist [17]. In case of a positive answer, physical ex-
amination would be performed, followed by diagnostic imag-
ing of the calf veins, if indicated, by venous duplex ultra-
sound. This treatment pathway also applies to patients pre-
senting themselves at the emergency ward or outpatient clinic
with complaints of calf pain.
Postoperative hemorrhage was confirmed when clinically
apparent (e.g., hematemesis or melena) or when visualized on
diagnostic imaging or during reoperation. In several cases,
hemorrhage was suspected based on clinical and chemical
parameters such as tachycardia, hypotension, severe abdomi-
nal pain in combination with a decrease in hemoglobin. In
these patients, no diagnostic imaging was performed and
tranexamic acid was administered pragmatically, 1000 mg
per dose, and repeated after a minimum of six hours if con-
sidered necessary by the surgeon. If a hemorrhage was not
confirmed by diagnostic imaging and the patient was hemo-
dynamically stable, cases were classified as ‘no hemorrhage’.
Statistical Analysis
All analyses were performed using SPSS (PASW) 25 software
(SPSS Inc., Chicago, Illinois, USA). The risk of VTE in the
two cohorts with different thromboprophylaxis regimens was
compared using the binomial test, testing the hypothesis that
not more than three VTE cases occur when restricted
thromboprophylaxis regimen II is implemented. For patients
without anticoagulants use, risks of hemorrhage in the two
regimens were compared using Fisher ’s Exact test.
Moreover, the adjusted risk of hemorrhage was analyzed with
multivariable binary logistic regression analysis, with pres-
ence of hemorrhage as the dependent variable and the two
thromboprophylaxis regimens (one dummy variable) as inde-
pendent variables, adjusting for patient characteristics, type of
surgery and presence of comorbidities. All characteristics
listed in Table 2 were also included to avoid that differences
between regimens I and II could be attributed to differences in
casemix between regimens. A similar multivariable logistic
regression analysis was performed to assess the difference in
risk of postoperative hemorrhage between patients with and
without anticoagulant use. Results were evaluated at a signif-
icance threshold of p < 0.05 (two-sided).
Results
Between 2014 and 2018, 3666 patients underwent a primary
RYGB (n = 1983) or SG (n = 1683). Over the years, popular-
ity of the sleeve gastrectomy as opposed to the RYGB gradu-
ally increased from 296/669 (44.2%) in 2014 to 437/777
Table 1 Caprini score and
treatment per patient group Patient group Treatment
Therapeutic anticoagulants
• Vitamin K antagonists
• Direct Oral Anticoagulant (DOAC)
• Low Molecular Weight Heparin (LMWH)
Pre- and postoperative bridging with Dalteparin 1 dd
5000 IE, continue until INR is adequate
One or more risk factors:
• Age ≥ 75 years
• Medical history of VTE
• Known hereditary thrombophilia*
• Recent cerebrovascular accident (≤ 1 month)
• Malignancy
Dalteparin 5000 IE from 1 day pre-operatively
until 14 days postoperatively
In case of medical history of VTE: Patient wears
own stockings
No risk factors Dalteparin 1 dd 5000 IE during hospital admission
*For example protein C-, protein S-, or antithrombin-deficiencies, factor V Leiden, prothrombin 20210A
mutation
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(56.2%) in 2018. Table 2 shows the baseline characteristics
and comorbidities for the two thromboprophylaxis regimens.
Significant differences were found between the two regimens
for baseline BMI, type of surgery, type 2 diabetes (T2D) and
hypercholesterolemia. Table 3 shows the baseline characteris-
tics divided by anticoagulant usage. Patients who used antico-
agulants were more often males of older age, and had higher
rates of hypertension, diabetes and dyslipidemia compared to
patients without anticoagulant use.
Two patients were diagnosed with postoperative VTE in
regimen I (2014–17): 2/2599 (0.01%, exact 95%CI: 0.0–
0.3%). In regimen II (2018) the postoperative VTE rate was
0/720 (0%, exact 95%CI: 0.0%–0.51%), hereby not exceed-
ing the pre-set threshold of three VTE cases (exact binomial
test, p > 0.99). Both patients diagnosed with VTE had devel-
oped early postoperative complications prior to the VTE oc-
currence, and did therefore not follow the fast-track protocol.
The absolute hemorrhage rates for patients without antico-
agulants use were 34/2599 (1.3%, exact 95%CI 0.9–1.8%) for
regimen I (2014–17) and 8/720 (1.1%, exact 95%CI 0.5–
2.2%) for regimen II (cohort 2018) (p = 0.675). The
thromboprophylaxis regimen in the group not on anticoagu-
lant therapy was not significantly associated with higher post-
operative hemorrhage rates, adjusted for patient characteris-
tics, type of surgery and comorbidities: OR 1.370, 95%CI
0.577–3.254, p = 0.475.
The absolute hemorrhage rate for the group with
preexisting anticoagulant use was 6.1% (95%CI: 3.9–8.9%)
versus 1.3% (95%CI: 0.9–1.7%) without anticoagulant use
(Fig. 1). Anticoagulant use was significantly associated with
postoperative hemorrhage: OR 3.143, 95%CI 1.642–6.019,
p = 0.001, adjusted for patient characteristics, type of surgery
and comorbidities.
In the period of 2014–2016, before the introduction of
tranexamic acid, 33/2114 patients (1.6%, exact 95%CI 1.1–
2.2%) had a postoperative hemorrhage requiring a
reintervention. Of the 1552 patients that underwent a metabol-
ic procedure in 2017–2018 (after implementation of
tranexamic acid), 24 (1.5%) patients received tranexamic acid
and still underwent a reintervention due to hemorrhage. Six
additional (0.4%) patients underwent a reintervention, but did
not receive tranexamic prior to this. Another 35 (2.3%) pa-
tients received tranexamic acid and did not undergo a
reintervention.
Discussion
This study aimed to determine the safety of a restricted policy
of pharmacological prophylaxis for VTE in patients undergo-
ing metabolic surgery with no or few risk factors besides their
obesity, and to determine the risk of postoperative bleeding
Table 3 Baseline characteristics






Female, n (%) 231 (66.6%) 2737 (82.5%) <0.001
Age (years), mean ± sd 50.6 ± 8.9 40.5 ± 11.0 <0.001
Baseline BMI (kg/m2),
mean ± sd
42.2 ± 5.2 43.3 ± 4.8 <0.001
RYGB, n (%) 214 (61.7%) 1769 (53.3%) <0.001
Presence of hypertension, n (%) 196 (57.3%) 821 (24.7%) <0.001
Presence of T2D, n (%) 110 (32.2%) 478 (14.4%) <0.001
Presence of dyslipidemia, n (%) 143 (41.8%) 341 (10.3%) <0.001
Table 2 Baseline characteristics based on thromboprophylaxis regimen
No anticoagulants use; 2 weeks
thromboprophylaxis
(regimen I, n = 2599)
No anticoagulants use;
thromboprophylaxis during
hospitalization (regimen II, n = 720)
p value
Female, n (%) 2145 (82.5%) 592 (82.2%) 0.847
Age (years), mean ± sd 40.5 ± 11.0 40.1 ± 11.4 0.759
Baseline BMI (kg/m2), mean ± sd 43.4 ± 4.8 42.8 ± 4.9 0.001
RYGB, n (%) 1460 (56.2%) 309 (42.9%) <0.001
Presence of hypertension, n (%) 655 (25.2%) 166 (24.1%) 0.552
Presence of T2D, n (%) 404 (15.6%) 74 (10.8%) 0.001
Presence of dyslipidemia, n (%) 300 (11.6%) 41 (6.0%) <0.001
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under different pharmacological thromboprophylaxis proto-
cols. This study showed that a VTE was observed in none of
the patients managed according to the restricted
thromboprophylaxis protocol. A total of two of the patients
with an intention-to-treat according to the fast-track protocol
deve loped a VTE , bo th w i t h ex t ended use o f
thromboprophylaxis. Adequate thromboprophylaxis is con-
sidered to be of great importance because of the highmortality
rate associated with VTE [8]. Therefore, the ERABS guide-
lines recommend both pharmacological prophylaxis and com-
pression devices of the lower extremities [7]. Quick mobiliza-
tion after surgery might be an even more important aspect in
preventing VTE. In the fast-track setting, mobilization starts
directly after surgery. On the first postoperative day, physical
therapists practice mobilization and advise patients on how to
mobilize after discharge.
Before the introduction of fast-track programs, VTE was a
feared complication of metabolic surgery and a significant
contributor of the mortality associated with these procedures
[18]. In 2007, Raftopoulos et al. concluded that extended
thromboprophylaxis was safe and effective in reducing the
i nc idence o f VTE as compa r ed to i n -ho sp i t a l
thromboprophylaxis only [19]. The authors mention a mean
duration of surgery of 220 min. The current study showed a
mean duration of surgery of 53 min for RYGB and 36 min for
SG in our cohort, supporting the earlier findings that duration
of surgery independently influences the risk of VTE [20].
Nowadays, the incidence of VTE after laparoscopic meta-
bolic surgery is relatively low [8] which is also confirmed in
our study: only two patient developed VTEs. Interestingly,
these patients did not follow the fast-track protocol because
of short-term postoperative complications. In one case, the
patient was readmitted within one week postoperatively and
underwent a reoperation because of staple line leakage.
During a two month hospital admission because of persistent
staple line leakage and the patient being bedridden and in a
poor clinical condition, the patient eventually developed a
DVT while on thromboprophylaxis. In the second case, the
pharmacological thromboprophylaxis was paused directly af-
ter surgery, because of suspicion of postoperative hemorrhage
that was later confirmed on diagnostic imaging. After several
days of bedrest due to poor clinical condition and no safe
possibility to administer thromboprophylaxis, pulmonary
embolisms occurred. These two cases emphasize the impor-
tance of close monitoring for the presence of VTE in patients
that do not follow the fast-track protocol.
The importance of close monitoring of patients with an
extended length of hospital stay was also shown by
Froehling et al. The authors state that the incidence of VTE
rose from 0.3% to 1.9% between thromboprophylaxis for sev-
en and 30 days postoperatively [21]. However, the patients
that developed VTEs had a mean length of hospital stay of
six days. In the current study, the median length of hospital
stay was 1.16 days.
Our results, supported by the available literature, demon-
strate that a short length of hospital stay (during which mobi-
lization is encouraged) can be beneficial for patients.
However, the window to detect complications during admis-
sion is small. It is suggested that the incidence of major bleed-
ing is increasing [10]. More specifically, postoperative hem-
orrhage occurs in 2.0% of patients undergoing SG and in 1.5–
3.1% of patients undergoing a RYGB [22, 23]. While our
results are in line with these rates (2.2% for SG and 1.3%
for RYGB), our study does not corroborate the increasing
trend.
As expected, the rates of postoperative hemorrhage were
higher in patients using anticoagulants. Also, this patient
group had higher rates of hypertension, diabetes and dyslipid-
emia, suggesting that these patients’ clinical condition was
already worse preoperatively. The study by Coblijn et al.
found that the use of anticoagulants is associated with postop-
erative complications (OR 1.5, 95%CI 0.884–2.394, p =
0.142) [24]. Our results correspond to these findings.
Postoperative hemorrhage can have a very serious course
and prevention of hemorrhage should therefore receive at least
equal attention as prevention of VTE. In 2017–2018, patients
that were suspected of postoperative hemorrhage were given
tranexamic acid, a plasminogen inhibitor that can reduce
blood loss by inhibiting fibrinolysis [25]. This decision was
mainly influenced by the patient’s clinical condition, the direct
availability of an operating room and the surgeon-on-call’s
experience with tranexamic acid. Klaassen et al. performed a
retrospective analysis on postoperative administration of
tranexamic acid in case of suspected hemorrhage and sug-
gested that tranexamic acid can reduce the reoperation rate
for bleeding after metabolic surgery [26]. Our retrospective
study has insufficient power to draw a conclusion on the pos-
sible prevention of reoperations due to administration of
tranexamic acid. Because of the increasing experience with
Fig. 1 Crude postoperative hemorrhage rates per thromboprophylaxis
regimen. There were no significant differences in hemorrhage rates by
thromboprophylaxis regimen either including (p = 0.674, gray bars) or
excluding (p = 0.675, black bars) patients with anticoagulant use
OBES SURG (2020) 30:553–559 557
tranexamic acid over the years and the negligible disadvan-
tages, the threshold to prescribe tranexamic acid in case of
suspicion of hemorrhage is currently low. A randomized con-
trolled trial should further investigate the effects of tranexamic
acid administration on the reoperations rates for hemorrhage.
Many studies report on either the risk of VTE or the risk of
postoperative hemorrhage. No articles were found on the op-
timal balance between VTE risk and hemorrhage risk in pa-
tients undergoing metabolic surgery and following a fast-track
program. Altieri et al. do report on both the risk of VTE and
the risk of hemorrhage and conclude that postoperative VTE
chemoprophylaxis is associated with decreased VTE events
compared to no prophylaxis, while minimizing hemorrhage
compared to pre-operative prophylaxis [27]. However, their
patients did not follow a fast-track protocol, which is known to
accelerate mobilization and shorten hospital stay. To our
knowledge, this article is the first to demonstrate that a restrict-
ed thromboprophylaxis strategy for certain low-risk patients
while following the fast-track protocol does not increase the
risk of VTE.
This study has several limitations. It was a single-center, ret-
rospective study and cohorts were consecutive instead of parallel
in time. However, these factors did not contribute to heterogene-
ity of the cohorts, except for the type of surgery. The sample size
of regimen II was limited, VTE is a rare event and observedVTE
incidence rates were low. A formal comparison of regimens I and
II in a randomized controlled trial would require at least 98,000
patients per treatment arm to demonstrate the superiority of reg-
imen II, and a non-inferiority study probably would require even
more patients. Such an unrealistically large study would clearly
be unfeasible. As such, our study does not demonstrate in abso-
lute terms that regimen II is superior (or non-inferior) to regimen
I. However, what our study actually does show is that it is highly
likely that the observed VTE rate of regimen II is below a rea-
sonably chosen threshold of three VTE cases. Also, routine ve-
nous duplex ultrasound was not performed. Therefore, only clin-
ically significant VTEs could be registered, and there may have
been some underreporting. However, it is unclear whether the
not-clinically apparent VTEs are relevant to diagnose and should
receive aggressive therapy when diagnosed. Unfortunately, due
to the retrospective aspect of this study, it was not possible to
perform a valid comparative analysis on the effects of tranexamic
acid on postoperative hemorrhage. Therefore, the results were
stated purely in descriptive terms and we refrained from any
conclusions regarding tranexamic acid use. We aim to address
this matter in future research projects.
Conclusion
This study demonstrates that a restricted thromboprophylaxis
strategy did not adversely affect the rates of VTE and postop-
erative hemorrhage for patients following the fast-track
protocol with no preexisting risk factors for VTE.
Furthermore, our study underlines that patients using antico-
agulants have an increased risk of postoperative hemorrhage
as compared to patients not on anticoagulant therapy. From
our data, we cannot conclude if administration of tranexamic
acid for clinical suspicion of hemorrhage could prevent
reintervention after metabolic surgery. Large national data-
bases could play an important role in further research on the
topic of short term thromboprophylaxis. Also, future studies
should focus on prevention of postoperative hemorrhage in
patients with a restricted thromboprophylaxis strategy follow-
ing the fast-track protocol.
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